$BBIO
BridgeBio Pharma, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021936 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $1.870M $338.0K $2.344M
YoY Change -85.49% -85.58% -71.16%
Cost Of Revenue $647.0K $739.0K $1.454M
YoY Change -58.28% -49.17%
Gross Profit $1.223M -$401.0K $890.0K
YoY Change -89.21% -145.06% -89.05%
Gross Profit Margin 65.4% -118.64% 37.97%
Selling, General & Admin $31.86M $31.19M $46.08M
YoY Change -41.8% -32.32% 27.95%
% of Gross Profit 2605.23% 5177.98%
Research & Development $90.90M $92.51M $104.3M
YoY Change -25.61% -11.31% 13.31%
% of Gross Profit 7432.71% 11719.66%
Depreciation & Amortization $1.660M $1.645M $265.0K
YoY Change 8.78% 520.75%
% of Gross Profit 135.73% 29.78%
Operating Expenses $122.8M $123.7M $150.4M
YoY Change -30.62% -17.75% 17.43%
Operating Profit -$121.5M -$129.1M -$149.5M
YoY Change -26.61% -13.63% 24.65%
Interest Expense -$15.90M $19.83M $11.07M
YoY Change 6.33% 79.14% 1.26%
% of Operating Profit
Other Income/Expense, Net $4.560M -$11.08M -$11.52M
YoY Change -83.88% -3.82% 12.6%
Pretax Income -$140.6M -$140.2M -$161.0M
YoY Change -7.69% -12.93% 23.7%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$137.6M -$140.2M -$161.0M
YoY Change -6.51% -12.93% 23.7%
Net Earnings / Revenue -7357.81% -41477.22% -6869.28%
Basic Earnings Per Share -$0.93 -$1.06
Diluted Earnings Per Share -$0.92 -$0.93 -$1.063M
COMMON SHARES
Basic Shares Outstanding 149.5M 148.2M 146.7M
Diluted Shares Outstanding 147.9M 146.7M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $471.9M $558.3M $599.6M
YoY Change -43.59% -6.89% -15.63%
Cash & Equivalents $376.7M $483.2M $180.3M
Short-Term Investments $95.23M $108.7M $419.3M
Other Short-Term Assets $76.93M $50.24M $39.64M
YoY Change 47.39% 26.76% 48.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $548.9M $642.2M $639.7M
YoY Change -38.25% 0.39% -14.18%
LONG-TERM ASSETS
Property, Plant & Equipment $14.57M $15.60M $27.74M
YoY Change -51.54% -43.75% 7.52%
Goodwill
YoY Change
Intangibles $28.71M $29.31M $46.20M
YoY Change -36.1% -36.56%
Long-Term Investments $33.66M $17.71M
YoY Change 90.11%
Other Assets $20.22M $29.87M $33.05M
YoY Change -38.77% -9.63% 100.33%
Total Long-Term Assets $74.18M $86.52M $141.8M
YoY Change -40.14% -38.99% 235.26%
TOTAL ASSETS
Total Short-Term Assets $548.9M $642.2M $639.7M
Total Long-Term Assets $74.18M $86.52M $141.8M
Total Assets $623.0M $728.7M $781.5M
YoY Change -38.48% -6.75% -0.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.56M $10.16M $12.04M
YoY Change -2.74% -15.6% 22.81%
Accrued Expenses $101.7M $105.0M $83.51M
YoY Change -17.23% 25.73% 37.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $283.0K
YoY Change
Total Short-Term Liabilities $121.4M $119.2M $95.82M
YoY Change -10.1% 24.39% 26.58%
LONG-TERM LIABILITIES
Long-Term Debt $431.0M $1.699B $103.1M
YoY Change 0.06% 1547.01% -78.14%
Other Long-Term Liabilities $26.64M $28.23M $27.58M
YoY Change 20.73% 2.35% 27.09%
Total Long-Term Liabilities $457.6M $28.23M $130.7M
YoY Change 1.06% -78.41% -73.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $121.4M $119.2M $95.82M
Total Long-Term Liabilities $457.6M $28.23M $130.7M
Total Liabilities $1.868B $1.859B $1.517B
YoY Change -0.55% 22.52% 143.21%
SHAREHOLDERS EQUITY
Retained Earnings -$1.918B -$1.781B -$1.290B
YoY Change 33.49% 38.05%
Common Stock $938.9M $917.5M $821.4M
YoY Change 11.55% 11.7%
Preferred Stock
YoY Change
Treasury Stock (at cost) $275.0M $275.0M $275.0M
YoY Change 0.0% 0.0% 266.67%
Treasury Stock Shares $6.192M $6.192M $6.192M
Shareholders Equity -$1.255B -$1.138B -$743.4M
YoY Change
Total Liabilities & Shareholders Equity $623.0M $728.7M $781.5M
YoY Change -38.48% -6.75% -0.78%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$137.6M -$140.2M -$161.0M
YoY Change -6.51% -12.93% 23.7%
Depreciation, Depletion And Amortization $1.660M $1.645M $265.0K
YoY Change 8.78% 520.75%
Cash From Operating Activities -$93.24M -$135.2M -$121.6M
YoY Change -30.36% 11.19% -7.68%
INVESTING ACTIVITIES
Capital Expenditures $801.0K $741.0K -$6.462M
YoY Change -131.59% -111.47% 1074.91%
Acquisitions
YoY Change
Other Investing Activities $18.77M $146.1M $65.43M
YoY Change -22.89% 123.32% -247.03%
Cash From Investing Activities $17.96M $146.9M $58.97M
YoY Change -17.59% 149.05% -230.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.377M 1.445M -135.5M
YoY Change -98.04% -101.07% -4972.52%
NET CHANGE
Cash From Operating Activities -93.24M -135.2M -121.6M
Cash From Investing Activities 17.96M 146.9M 58.97M
Cash From Financing Activities 6.377M 1.445M -135.5M
Net Change In Cash -68.90M 13.14M -198.0M
YoY Change -132.3% -106.63% 13.85%
FREE CASH FLOW
Cash From Operating Activities -$93.24M -$135.2M -$121.6M
Capital Expenditures $801.0K $741.0K -$6.462M
Free Cash Flow -$94.04M -$135.9M -$115.1M
YoY Change -28.41% 18.08% -12.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
bbio Cost Of License Revenue And Products Sold
CostOfLicenseRevenueAndProductsSold
2787000
bbio Cost Of License Revenue And Products Sold
CostOfLicenseRevenueAndProductsSold
1563000
bbio Fair Value Of Shares Issued Under License Agreements
FairValueOfSharesIssuedUnderLicenseAgreements
4567000
us-gaap Accretion Expense
AccretionExpense
6469000
CY2022Q3 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
24581000
CY2021Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
19749000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
25661000
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
49148000
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001743881
us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38959
dei Entity Registrant Name
EntityRegistrantName
BridgeBio Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1850815
dei Entity Address Address Line1
EntityAddressAddressLine1
421 Kipling Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94301
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
391-9740
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BBIO
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
149483134
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
483235000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
393772000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
75080000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
393743000
CY2022Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
33662000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32446000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
642219000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
888858000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15603000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30066000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11738000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15907000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
29310000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
44934000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
29870000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33027000
CY2022Q3 us-gaap Assets
Assets
728740000
CY2021Q4 us-gaap Assets
Assets
1012792000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10158000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11884000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
24842000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
37041000
CY2022Q3 bbio Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
44564000
CY2021Q4 bbio Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
44138000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4230000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6786000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4044000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4938000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7518000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
23838000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30282000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
119194000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
135069000
CY2022Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
422972000
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
430752000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13000000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17428000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28226000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22069000
us-gaap Accretion Expense
AccretionExpense
4043000
CY2022Q3 us-gaap Liabilities
Liabilities
1859113000
CY2021Q4 us-gaap Liabilities
Liabilities
1878371000
CY2022Q3 bbio Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests
-2388000
CY2021Q4 bbio Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests
1423000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
155558848
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
149367087
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
153535084
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
147343323
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
156000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
154000
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
6191761
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6191761
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
275000000
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
275000000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
917333000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
841530000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-348000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-132000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1780558000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1436966000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1138417000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-870414000
CY2022Q3 us-gaap Minority Interest
MinorityInterest
10432000
CY2021Q4 us-gaap Minority Interest
MinorityInterest
3412000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1127985000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-867002000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
728740000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1012792000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
338000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2344000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
75778000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56830000
CY2022Q3 bbio Cost Of License Revenue And Products Sold
CostOfLicenseRevenueAndProductsSold
739000
CY2021Q3 bbio Cost Of License Revenue And Products Sold
CostOfLicenseRevenueAndProductsSold
1454000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
92511000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
104305000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
308560000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
328824000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31188000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46084000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
111327000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
137461000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
5016000
us-gaap Restructuring Charges
RestructuringCharges
36074000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
129454000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
151843000
us-gaap Costs And Expenses
CostsAndExpenses
458748000
us-gaap Costs And Expenses
CostsAndExpenses
467848000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-129116000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-149499000
us-gaap Operating Income Loss
OperatingIncomeLoss
-382970000
us-gaap Operating Income Loss
OperatingIncomeLoss
-411018000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2417000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
234000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3450000
us-gaap Investment Income Interest
InvestmentIncomeInterest
951000
CY2022Q3 us-gaap Interest Expense
InterestExpense
19825000
CY2021Q3 us-gaap Interest Expense
InterestExpense
11067000
us-gaap Interest Expense
InterestExpense
60448000
us-gaap Interest Expense
InterestExpense
31644000
bbio Gain From Sale Of Priority Review Voucher Net
GainFromSaleOfPriorityReviewVoucherNet
107946000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6331000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-684000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12060000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7539000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11077000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11517000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
38888000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-23154000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-140193000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-161016000
us-gaap Profit Loss
ProfitLoss
-344082000
us-gaap Profit Loss
ProfitLoss
-434172000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2854000
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-5081000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-490000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-18810000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-137339000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-155935000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-343592000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-415362000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
147937817
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147937817
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146662756
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146662756
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146842453
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146842453
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
144044360
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
144044360
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-140193000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-161016000
us-gaap Profit Loss
ProfitLoss
-344082000
us-gaap Profit Loss
ProfitLoss
-434172000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-216000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-173000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-140114000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-161033000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-344298000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-434345000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2854000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-5081000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-490000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-18810000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-137260000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-155952000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-343808000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-415535000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-867002000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25423000
CY2022Q1 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
89000
CY2022Q1 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
48000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-251000
CY2022Q1 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-200290000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1041023000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23901000
CY2022Q2 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
4686000
CY2022Q2 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-144000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2022Q2 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-580000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1013514000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
451000
CY2022Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
596000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23231000
CY2022Q3 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
77000
CY2022Q3 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-65000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
CY2022Q3 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-139240000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1127985000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
106256000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19841000
CY2021Q1 bbio Adjustments To Additional Paid In Capital Purchase Of Capped Calls
AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls
-61295000
CY2021Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
50000000
CY2021Q1 bbio Repurchase Of Noncontrolling Interests Transaction Costs
RepurchaseOfNoncontrollingInterestsTransactionCosts
70734000
CY2021Q1 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-91997000
CY2021Q1 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
5080000
CY2021Q1 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-517000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-249000
CY2021Q1 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-170206000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-389365000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32509000
CY2021Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
5308000
CY2021Q2 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
5000
CY2021Q2 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
3618000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
93000
CY2021Q2 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-100512000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-457490000
CY2021Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
144692000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16896000
CY2021Q3 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
640000
CY2021Q3 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
362000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2021Q3 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-159680000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-738841000
us-gaap Profit Loss
ProfitLoss
-344082000
us-gaap Profit Loss
ProfitLoss
-434172000
us-gaap Share Based Compensation
ShareBasedCompensation
69770000
us-gaap Share Based Compensation
ShareBasedCompensation
79731000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5111000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4317000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-12969000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-1510000
bbio Gain From Sale Of Priority Review Voucher Excluding Transaction Costs
GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts
110000000
bbio Gain From Recognition Of Receivable From Licensing And Collaboration Agreements
GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements
12500000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1446000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
459000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6261000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
12720000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
3300000
bbio Call Option Expense Income
CallOptionExpenseIncome
-5550000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-4687000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-7322000
bbio Increase Decrease Receivable From Licensing And Collaboration Agreements
IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements
832000
bbio Increase Decrease Receivable From Licensing And Collaboration Agreements
IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements
7710000
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
462000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4072000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3743000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10095000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
8930000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1725000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1360000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-9122000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4443000
bbio Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
452000
bbio Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
4686000
bbio Increase Decrease In Accrued Professional Service
IncreaseDecreaseInAccruedProfessionalService
-2556000
bbio Increase Decrease In Accrued Professional Service
IncreaseDecreaseInAccruedProfessionalService
346000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4819000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4474000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
16969000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3797000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1629000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-326251000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-364039000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
134635000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
575478000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
452819000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
305200000
bbio Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
98925000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
26312000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
23960000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
28830000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
4743000
bbio Proceeds From Consolidation Of Entities
ProceedsFromConsolidationOfEntities
13654000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1500000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
35000000
bbio Proceeds From Sale Of Priority Review Voucher
ProceedsFromSaleOfPriorityReviewVoucher
110000000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
10000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4020000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10710000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
435182000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-222626000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
747500000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
16064000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1120000
bbio Purchase Of Capped Calls
PurchaseOfCappedCalls
61295000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
198458000
bbio Proceeds From Issuance Of Noncontrolling Interest
ProceedsFromIssuanceOfNoncontrollingInterest
3500000
bbio Repurchase Of Noncontrolling Interest Including Direct Transaction Costs
RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts
85090000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
25000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
20486000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
18108000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2558000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3821000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1072000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4035000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
609000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14294000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-19511000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
411065000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
89420000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-175600000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
396365000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
358679000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
485785000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183079000
us-gaap Interest Paid Net
InterestPaidNet
47575000
us-gaap Interest Paid Net
InterestPaidNet
28239000
bbio Payment In Kind Interest Added To Principal Of Term Loan
PaymentInKindInterestAddedToPrincipalOfTermLoan
8503000
bbio Net Non Cash Portion Of Repurchase Of Noncontrolling Interests
NetNonCashPortionOfRepurchaseOfNoncontrollingInterests
38167000
bbio Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets
DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets
8749000
bbio Noncash Or Part Noncash Contributions Made By Noncontrolling Interests
NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests
21600000
bbio Recognized Intangible Asset Recorded In Accrued Research And Development Liabilities
RecognizedIntangibleAssetRecordedInAccruedResearchAndDevelopmentLiabilities
11000000
bbio Recognized Intangible Asset Recorded In Accrued Research And Development Liabilities
RecognizedIntangibleAssetRecordedInAccruedResearchAndDevelopmentLiabilities
12500000
us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
2449000
bbio Repurchase Of Common Stock Recorded In Accounts Payable
RepurchaseOfCommonStockRecordedInAccountsPayable
1542000
bbio Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
1153000
bbio Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
-221000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
483235000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180347000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
140000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
176000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2410000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2556000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
485785000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183079000
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
8514000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div id="organizationanddescription" style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization and De</span><span id="n1_organization_description_business"/><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">scription of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest, and variable interest entities (“VIEs”) for which BridgeBio is the primary beneficiary (collectively, “we”, “our”, “us”). BridgeBio is headquartered in Palo Alto, California.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassifications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain reclassifications have been made to the condensed consolidated statement of cash flows for the nine months ended September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to conform to the current year’s presentation. These reclassifications had no net effect on cash flows from operating, financing and investing activities as previously reported.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 bbio Estimated Fair Value Of Outstanding Term Loan
EstimatedFairValueOfOutstandingTermLoan
386400000
CY2021Q1 bbio Leo Call Option Liability Current
LEOCallOptionLiabilityCurrent
0
bbio Call Option Expense Income
CallOptionExpenseIncome
-5600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accruals for research and development activities and contingent clinical, development, regulatory, and sales-based milestone payments in our in-licensing agreements and asset acquisitions, </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accruals for performance-based milestone compensation arrangements, </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">determining and allocating the transaction price to performance obligations for transactions accounted for under ASC 606,</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expected recoverability and estimated useful lives of our long-lived assets, and</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additional charges as a result of, or that are associated with, any restructuring initiative.</span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We base our estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2022Q3 bbio Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2021Q4 bbio Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2022Q3 bbio Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2021Q4 bbio Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2022Q3 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
1745000
CY2021Q3 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
651000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
360000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
664000
CY2021Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-1057000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-13329000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-2174000
CY2022Q3 bbio Net Gains Losses Included In Other Income Expense Net
NetGainsLossesIncludedInOtherIncomeExpenseNet
10259000
CY2021Q3 bbio Net Gains Losses Included In Other Income Expense Net
NetGainsLossesIncludedInOtherIncomeExpenseNet
-406000
bbio Net Gains Losses Included In Other Income Expense Net
NetGainsLossesIncludedInOtherIncomeExpenseNet
-12969000
bbio Net Gains Losses Included In Other Income Expense Net
NetGainsLossesIncludedInOtherIncomeExpenseNet
-1510000
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
450617000
CY2022Q3 bbio Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
-27000
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
450590000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
526018000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
348000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
525670000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
233103000
CY2021Q4 bbio Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
-2000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
233101000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
626976000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
134000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
626844000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
bbio Short Term Marketable Securities Contractual Maturities
ShortTermMarketableSecuritiesContractualMaturities
P7M15D
CY2021 bbio Short Term Marketable Securities Contractual Maturities
ShortTermMarketableSecuritiesContractualMaturities
P6M
CY2022Q3 bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-300000
bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
1200000
CY2021Q3 bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-500000
bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-200000
CY2022Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
700000
CY2021Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
2100000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
21666000
CY2021Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
871000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2458000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
8514000
us-gaap Interest Expense Debt
InterestExpenseDebt
24124000
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y2M12D
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32500000
CY2021 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y9M18D
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
47500000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3190000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2566000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
29310000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44934000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
600000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
2400000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
2400000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
2400000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
2400000
CY2022Q3 bbio Finite Lived Intangible Assets Amortization Expense Rolling After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour
19100000
CY2022Q3 bbio Potential Milestone Fixed Monetary Amount Settlement In Cash
PotentialMilestoneFixedMonetaryAmountSettlementInCash
10035000
CY2022Q3 bbio Potential Milestone Accrued Amount Settlement In Cash
PotentialMilestoneAccruedAmountSettlementInCash
744000
CY2022Q3 bbio Potential Milestone Fixed Monetary Amount Settlement In Stock
PotentialMilestoneFixedMonetaryAmountSettlementInStock
77269000
CY2022Q3 bbio Potential Milestone Accrued Amount Settlement In Stock
PotentialMilestoneAccruedAmountSettlementInStock
9155000
CY2022Q3 bbio Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion
PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion
111648000
CY2022Q3 bbio Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion
PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion
2432000
CY2022Q3 bbio Potential Milestone Fixed Monetary Settlement Amount
PotentialMilestoneFixedMonetarySettlementAmount
198952000
CY2022Q3 bbio Potential Milestone Accrued Settlement Amount
PotentialMilestoneAccruedSettlementAmount
12331000
CY2021Q4 bbio Accrued Termination Charges
AccruedTerminationCharges
0
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7643000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
22927000
CY2022Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
895000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2668000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
8538000
us-gaap Interest Expense Debt
InterestExpenseDebt
25595000
CY2021Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7643000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1128000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1457000
us-gaap Operating Lease Cost
OperatingLeaseCost
4017000
us-gaap Operating Lease Cost
OperatingLeaseCost
4078000
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
110000
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
115000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
334000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
288000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1567000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1111000
us-gaap Variable Lease Cost
VariableLeaseCost
4632000
us-gaap Variable Lease Cost
VariableLeaseCost
2831000
CY2022Q3 us-gaap Lease Cost
LeaseCost
2805000
CY2021Q3 us-gaap Lease Cost
LeaseCost
2683000
us-gaap Lease Cost
LeaseCost
8983000
us-gaap Lease Cost
LeaseCost
7197000
us-gaap Operating Lease Payments
OperatingLeasePayments
4819000
us-gaap Operating Lease Payments
OperatingLeasePayments
4474000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
317000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
101000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
240000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6380000
CY2022Q3 bbio Percentage Of Excise Tax Benefit On Corporate Stock Buy Back
PercentageOfExciseTaxBenefitOnCorporateStockBuyBack
0.01
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y4M24D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M12D
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2021Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0576
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0558
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0662
CY2021Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0662
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1000000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4896000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3962000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3929000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1860000
CY2022Q3 bbio Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
4145000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19792000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2748000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
17044000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4044000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13000000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
17044000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
3300000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2600000
CY2019Q4 bbio One Time Fees Receivable Noncurrent
OneTimeFeesReceivableNoncurrent
10000000.0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18658000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
71244000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16130000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
83061000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 bbio Percentage Of Corporate Alternative Minimum Tax Rate
PercentageOfCorporateAlternativeMinimumTaxRate
0.15
CY2022Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
3952000
us-gaap Business Exit Costs1
BusinessExitCosts1
12945000
CY2022Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
67000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
12720000
CY2022Q3 us-gaap Severance Costs1
SeveranceCosts1
997000
us-gaap Severance Costs1
SeveranceCosts1
10409000
CY2022Q3 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
5016000
us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
36074000
CY2022Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
11223000
bbio Reclassification Of Final Payment Obligation Related To Manufacturing Agreement Recognized In Prior Period
ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod
2185000
CY2022Q3 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
5016000
us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
36074000
CY2022Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
9421000
us-gaap Payments For Restructuring
PaymentsForRestructuring
17616000
CY2022Q3 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
67000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
13892000
CY2022Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
6751000
CY2022Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
6751000
CY2022Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
6751000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
55789481
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39222976

Files In Submission

Name View Source Status
0000950170-22-021936-index-headers.html Edgar Link pending
0000950170-22-021936-index.html Edgar Link pending
0000950170-22-021936.txt Edgar Link pending
0000950170-22-021936-xbrl.zip Edgar Link pending
bbio-20220930.htm Edgar Link pending
bbio-20220930.xsd Edgar Link pending
bbio-ex31_1.htm Edgar Link pending
bbio-ex31_2.htm Edgar Link pending
bbio-ex32_1.htm Edgar Link pending
bbio-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
bbio-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bbio-20220930_def.xml Edgar Link unprocessable
bbio-20220930_lab.xml Edgar Link unprocessable
bbio-20220930_pre.xml Edgar Link unprocessable
bbio-20220930_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending